Altered folate receptor 2 expression in uraemic patients on haemodialysis: Implications for folate resistance

Nephrology Dialysis Transplantation

Volumn 28, Issue 5, 2013, Pages 1214-1224

  Perna, Alessandra F ^a   Lanza, Diana ^a   Sepe, Immacolata ^a   Conzo, Giovanni ^a   Altucci, Lucia ^a   Ingrosso, Diego ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

folate receptors; folates; haemodialysis; heterogeneous nuclear ribonucleoprotein E1; homocysteine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ERYTHROPOIETIN; FOLATE RECEPTOR 2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN E1; HOMOCYSTEINE; MESSENGER RNA; PREFOLIC; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION; HEMODIALYSIS; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UREMIA;

FOLATE RECEPTORS; FOLATES; HAEMODIALYSIS; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-E1; HOMOCYSTEINE;

BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHRONIC DISEASE; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; FOLATE RECEPTOR 2; FOLIC ACID; FOLLOW-UP STUDIES; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RENAL DIALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UREMIA;

EID: 84877932359     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs510     Document Type: Article

References (44)

1. Heinz J, Kropf S, Luley C et al. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis 2009; 54: 478-489
2. Perna AF, Ingrosso D, Violetti E et al. Hyperhomocysteinemia in uremia-a red flag in a disrupted circuit. Semin Dial 2009; 22: 351-356
3. Jardine MJ, Kang A, Zoungas S et al. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ 2012; 344: e3533
4. Huang T, Chen Y, Yang B et al. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin Nutr 0000; 31: 448-454
5. Massy ZA. Therapy of hyperhomocysteinemia in chronic kidney disease. Semin Nephrol 2006; 26: 24-27
6. Robinson K. Renal disease, homocysteine, and cardiovascular complications. Circulation 2004; 109: 294-295
7. Xiao X, Tang YS, Mackins JY et al. Isolation and characterization of a folate receptor mRNA-binding trans-factor from human placenta. Evidence favoring identity with heterogeneous nuclear ri-bonucleoprotein E1. J Biol Chem 2001; 276: 41510-7
8. Xiao S, Hansen DK, Horsley ET et al. Maternal folate deficiency results in selective upregulation of folate receptors and heterogeneous nuclear ribonucleoprotein-E1 associated with multiple subtle aberrations in fetal tissues. Birth Defects Res A Clin Mol Teratol 2005; 73: 6-28
9. 0-untranslated region of human folate receptor-alpha mRNA and a 46-kDa cytosolic transfactor is critical for translation. J Biol Chem 1996; 271: 25539-25547
10. Antony A, Tang YS, Khan RA et al. Translational upregulation of folate receptors is mediated by homocysteine via RNA-hetero-geneous nuclear ribonucleoprotein E1 interactions. J Clin Invest 2004; 113: 285-301
11. Tang YS, Khan RA, Zhang Y et al. Incrimination of heterogeneous nuclear ribonucleoprotein E1 (hnRNP-E1) as a candidate sensor of physiological folate deficiency. J Biol Chem 2011; 286: 39100-39115
12. Nakashima-Matsushita N, Homma T, Yu S et al. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 1609-1616
13. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994; 73: 2432-2443
14. Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci 2006; 11: 506-519
15. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004; 56: 1067-1084
16. Shen F, Ross JF, Wang X et al. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hemato-poietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 1994; 33: 1209-1215
17. Ross JF, Wang H, Behm FG et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999; 85: 348-357
18. Yan W, Ratnam M. Preferred sites of glycosylphosphatidylinosi-tol modification in folate receptors and constraints in the primary structure of the hydrophobic portion of the signal. Biochemistry 1995; 34: 14594-14600
19. Høier-Madsen M, Holm J, Hansen SI. α isoforms of soluble and membrane-linked folate-binding protein in human blood. Biosci Rep 2008; 28: 153-160
20. Antony AC, Bruno E, Briddell RA et al. Effect of perturbation of specific folate receptors during in vitro erythropoiesis. J Clin Invest 1987; 80: 1618-1623
21. Heine GH, Ortiz A, Massy ZA et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 2012; 8: 362-369
22. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248-254
23. Ponchel F, Toomes C, Bransfield K et al. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 2003; 3: 18
24. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-622
25. Capasso R, Sambri I, Cimmino A et al. Homocysteinylated albumin promotes increased monocyte-endothelial cell adhesion and up-regulation of MCP1, Hsp60 and ADAM17. PLoS One 2012; 7: e31388
26. Yi P, Pogribny I, Jill James S. Multiplex PCR for simultaneous detection of 677 C→T and 1298 A→C polymorphisms in methyle-netetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett 2002; 181: 209
27. Ismail SI, Ababneh NA, Khader Y et al. Methylenetetrahydrofo-late reductase genotype association with the risk of follicular lymphoma. Cancer Genet Cytogenet 2009; 195: 120-124
28. Perna AF, Luciano MG, Ingrosso D et al. Hydrogen sulphide-generating pathways in haemodialysis patients: a study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes. Nephrol Dial Transplant 2009; 24: 3756-3763
29. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Norwalk: Appleton & Lange, 1990, p. 199
30. Herrmann W, Obeid R, Schorr H et al. Functional vitamin B12 deficiency and determination of holotranscobalamin in populations at risk. Clin Chem Lab Med 2003; 41: 1478-1488
31. Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in endstage renal disease and is closely linked to plasma folate and pyri-doxine concentrations. Circulation 1996; 94: 2743-2748
32. Kumar J, Das SK, Sharma P et al. Homocysteine levels are associated with MTHFR A1298C polymorphism in Indian population. J Hum Genet 2005; 50: 655-663
33. Weisberg I, Tran P, Christensen B et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172
34. Ueland PM, Loscalzo J. Homocysteine and cardiovascular risk: the perils of reductionism in a complex system. Clin Chem 2012.187286 Published May 23, 2012.
35. Perna AF, Violetti E, Lanza D et al. Therapy of hyperhomocystei-nemia in hemodialysis patients: effects of folates and N-acetylcys-teine. J Ren Nutr 2012; 22: 507-514
36. Pan Y, Guo LL, Cai LL et al. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr 2012; 108: 400-407
37. Sunder-Plassmann G, Födinger M, Buchmayer H et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemo-dialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000; 11: 1106-1116
38. Ingrosso D, Cimmino A, Perna AF et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003; 361: 1693-1699
39. Zhang D, Fang P, Jiang X et al. Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice. Circ Res 2012; 111: 37-49
40. Carmel R, Vasireddy H, Aurangzeb I et al. High serum cobalamin levels in the clinical setting-clinical associations and holo-trans-cobalamin changes. Clin Lab Haem 2001; 23: 365-371
41. Hsueh CT, Dolnick BJ. Regulation of folate binding protein gene expression by DNA methylation in methotrexate-resistent KB cells. Biochem Pharmacol 1994; 47: 1019-1027
42. Perna AF, Satta E, Acanfora F et al. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 2006; 69: 869-876
43. Vanholder R, Baurmeister U, Brunet P et al. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008; 19: 863-870
44. Zheng X, Kelley K, Elnakat H et al. mRNA instability in the nucleus due to a novel open reading frame element is a major determinant of the narrow tissue specificity of folate receptor alpha. Mol Cell Biol 2003; 23: 2202-2212